Compounds of Formula I: ##STR00001##
wherein: one of X and X′ is N and the other of X and X′ is C, are described, along with compositions containing the same and methods of use thereof in the treatment of cancer.

The present invention provides compounds of Formula (I): ##STR00001##
or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of fXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.

The present invention provides compounds of Formula (I): ##STR00001##
or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of fXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.

The present invention provides for compounds of Formula I and embodiments and salts thereof for the treatment of diseases (e.g., neurodegenerative diseases). R.sup.1, R.sup.2, R.sup.3, X.sup.1, X.sup.2, A and Cy variable in Formula all have the meaning as defined herein.

##STR00001##

Energetic nitrogen-rich monomers represented by the general Formula I:

##STR00001##

wherein each of X1 and X2 is independently NR or a covalent bond. R is H or C1-4 alkyl, each of T1 and T2 is independently a moiety selected from the group consisting of a triazole moiety, a tetrazole moiety and a guanidine moiety, at least one of T1 and T2 being substituted by at least one polymerizable group, are disclosed herein, as well as polymers based thereon, and uses of such polymers.

The present invention relates to anhydrous tetraalkyl pnictogen perfluoroalkoxy salts and a process to produce anhydrous tetraalkyl pnictogen perfluoroalkoxy salts. The process involves contacting a hydrofluoroether and an amine to produce a tetraalkyl pnictogen perfluoroalkoxy salt in the presence of a solvent. The present invention also relates to processes of preparing fluoroalkyl ether acid fluoride polymers using tetraalkyl pnictogen perfluoroalkoxy salt. The present invention further relates to some novel fluorinated alkyl polyether polymers.

The present invention relates to anhydrous tetraalkyl pnictogen perfluoroalkoxy salts and a process to produce anhydrous tetraalkyl pnictogen perfluoroalkoxy salts. The process involves contacting a hydrofluoroether and an amine to produce a tetraalkyl pnictogen perfluoroalkoxy salt in the presence of a solvent. The present invention also relates to processes of preparing fluoroalkyl ether acid fluoride polymers using tetraalkyl pnictogen perfluoroalkoxy salt. The present invention further relates to some novel fluorinated alkyl polyether polymers.

The present disclosure relates generally to certain tricyclic compounds, pharmaceutical compositions comprising said compounds, and methods of making said compounds and pharmaceutical compositions. The compounds of the disclosure are useful in treating or preventing human immunodeficiency virus (HIV) infection.

The present disclosure relates generally to certain tricyclic compounds, pharmaceutical compositions comprising said compounds, and methods of making said compounds and pharmaceutical compositions. The compounds of the disclosure are useful in treating or preventing human immunodeficiency virus (HIV) infection.

Provided herein are novel substituted bridged urea and related analogs and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent. ##STR00001##